Solve it with DissolvIt, at RDD

  • 28 april, 2014
  • 16:12

At the RDD (Respiratory Drug Delivery to the Lungs) conference, May 4-8 Puerto Rico, Inhalation Sciences present a poster on DissolvIt, their in vitro dissolution and absorption test method for dry powders in the lungs.

The poster, co-written by GlaxoSmithKline UK, Inhalation Sciences and the Institute of Environmental Medicine, Karolinska Institutet, Stockholm, is titled The DissolvIt: An In Vitro Evaluation of the Dissolution and Absorption of Three Inhaled Dry Powder Drugs in the Lung. DissolvIt is a key in vitro module of the PreciseInhale System, Inhalation Sciences’ versatile, precision dosing dry powder inhalation research platform.

Maria Börjel: “There are a number of ways of simulating drug dissolution in the gastro-intestinal tract, but far fewer for simulating drug dissolution in the lungs, let alone with the kind of accuracy DissolvIt has shown. This poster details results that I think would be of interest to any early-stage inhalation and pulmonary researchers.”

Long-term big pharma involvement

Successful contract research with big pharma has been crucial in the development of DissolvIt. In 2009 AstraZeneca, with Inhalation Sciences and Karolinska Institutet, Stockholm, presented Experimental Approaches to Assess Particle Dissolution Rate In Vitro and Ex Vivo to the International Society for Aerosols in Medicine. A key conclusion in that poster was ‘DissolvIt can be a valuable tool for predicting dissolution time of inhaled pharmaceutical particles in the lung.’

Regulatory requirement benefits of in vitro research: 3Rs

By minimizing the use of animals in lab research, in vitro research also, usefully, offers inhalation researchers world-class data whilst keeping to the principles of 3R research (Replacing, Refining and Reducing the number of animals used in research.) With the number of independent and government foundations funding 3R research projects growing, a sophisticated in vitro system that delivers accurate results is a powerful plus for many researchers.

In vitro studies manager Maria Börjel: “We hope to meet more researchers and developers at RDD through this poster. I’d urge anyone interested in high-benefit, sophisticated in vitro research to read the poster and come and meet us. No matter what the challenge, we meet people’s needs. We never give up. We know how vital it is to talk closely with clients and find out their key challenge. RDD is a great chance for us to do just that.”

BENEFITS: DissolvIt gives preclinical pulmonary researchers:

  • Reliable data using milligrams not grams of test substance
  • Increased control PreciseInhale’s nine cover slips let you assess dose, before running up to six experiments in DissolvIt
  • Early elimination of drug candidates
  • Ranking of drug candidates
  • Meets 3R requirements (refinement, reduction, replacement) for minimizing animal use in medical research